Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 10:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 2,241 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: RNA sequencing Clear all
Completed Phase 1 Interventional

A Clinical Study That Will Assess the Effect of SEP-363856 and Prior Antipsychotic (PA) Standard of Care on Glucose and Regulation of Insulin in Patients With Schizophrenia

NCT05463770
View directory record Official record
Conditions
Schizophrenia
Interventions
SEP-363856
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
8
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Long Beach, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2024 · Synced Oct 17, 2026, 10:59 AM EDT
Completed Phase 1 Interventional

Bioequivalence Study of Azacitidine for Injection in Myelodysplastic Syndrome (MDS) Patients

NCT01152346
View directory record Official record
Conditions
Myelodysplastic Syndrome
Interventions
Azacitidine for Injection, Vidaza®
Drug
Lead sponsor
Bioniche Pharma USA LLC
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
4
States / cities
Anaheim, California • Corona, California • Fresno, California + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2015 · Synced Oct 17, 2026, 10:59 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Aging and Mixed Perturbation Training to Reduce Falls in Locomotion

NCT03199729
View directory record Official record
Conditions
Older Adults
Interventions
Slip-only training, Trip-only training, Combined slip+trip training
Other
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
60 Years to 90 Years
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 17, 2026, 10:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Adherence of 2 Strengths of Newly Manufactured Samples and Aged Samples of a New Formulation (JNJ-35685-AAA-G016 and JNJ-35685-AAA-G021) of Fentanyl Transdermal System Compared With Duragesic Fentanyl Transdermal Patch in Healthy Participants

NCT02608320
View directory record Official record
Conditions
Healthy
Interventions
Duragesic (Fentanyl Transdermal System [TDS] Small Patches), New JNJ-35685-AAA-G016 (Fentanyl TDS -Small Patches), Aged JNJ-35685-AAA-G016 (Fentanyl TDS Small Patches), Duragesic (Fentanyl TDS Large Patches), New JNJ-35685-AAA-G021 (Fentanyl TDS Large Patches), Aged JNJ-35685-AAA-G021 (Fentanyl TDS Large Patches)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 17, 2026, 10:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic and Pharmacodynamic Study in Healthy Subjects Comparing the Interactions Between E5501 and Verapamil and Cyclosporine.

NCT01437384
View directory record Official record
Conditions
Idiopathic Thrombocytopenic Purpura (ITP)
Interventions
E5501
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2011
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated May 21, 2012 · Synced Oct 17, 2026, 10:59 AM EDT
Completed No phase listed Observational

RNA Sequencing of Solid and Cystic Lesions of the Pancreas

NCT01807325
View directory record Official record
Conditions
Pancreas Cyst, Pancreas Mass
Interventions
pancreas biopsy
Procedure
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
2
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 10, 2020 · Synced Oct 17, 2026, 10:59 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

An Open-label, Two-period, Fixed-sequence Study to Evaluate Multiple-dose Itraconazole Effect on The Single-dose PK of PF-06372865 in Healthy Subjects

NCT02475746
View directory record Official record
Conditions
Healthy
Interventions
PF-06372865, itraconazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
2
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 26, 2017 · Synced Oct 17, 2026, 10:59 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

ADASUVE-Lorazepam Drug-Drug Interaction

NCT01877642
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Lorazepam 1 mg IM, Inhaled loxapine 10 mg, Inhaled Placebo, Placebo IM
Drug
Lead sponsor
Alexza Pharmaceuticals, Inc.
Other
Eligibility
18 Years to 50 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 13, 2017 · Synced Oct 17, 2026, 10:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalency Study of 7.5 mg Pilocarpine Tablets Under Fasting Conditions

NCT00602524
View directory record Official record
Conditions
Dry Mouth
Interventions
Pilocarpine
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 17, 2026, 10:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Study of CT1812 in Healthy Volunteers

NCT03716427
View directory record Official record
Conditions
Healthy Volunteers
Interventions
CT1812, tolbutamide, dextromethorphan, Omeprazole, midazolam
Drug
Lead sponsor
Cognition Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 23, 2018 · Synced Oct 17, 2026, 10:59 AM EDT
Completed Not applicable Interventional Results available

Comparative Study Between CellFX and Electrodessication in Sebaceous Hyperplasia (SH) Lesions

NCT04539886
View directory record Official record
Conditions
Skin Lesion, Skin Abnormalities, Sebaceous Hyperplasia
Interventions
CellFX System, Intralesional Electrodesiccation
Device
Lead sponsor
Pulse Biosciences, Inc.
Industry
Eligibility
21 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
5
States / cities
Scottsdale, Arizona • Edina, Minnesota • Charlotte, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2024 · Synced Oct 17, 2026, 10:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Dose Crossover Comparative Bioavailability and Food Effect Study of Two EMB-001 Formulations

NCT03404817
View directory record Official record
Conditions
Cocaine Use Disorder
Interventions
Original formulation EMB-001, New formulation EMB-001
Drug
Lead sponsor
Embera NeuroTherapeutics, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Jun 11, 2018 · Synced Oct 17, 2026, 10:59 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus

NCT02804763
View directory record Official record
Conditions
Systemic Lupus Erythematosus (SLE)
Interventions
Placebo, Dapirolizumab pegol (DZP)
Drug
Lead sponsor
UCB Biopharma S.P.R.L.
Industry
Eligibility
18 Years and older
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
25
States / cities
Birmingham, Alabama • El Cajon, California • Huntington Beach, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2021 · Synced Oct 17, 2026, 10:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Evaluation of Comfort for Two Marketed Daily Disposable Contact Lenses

NCT04968925
View directory record Official record
Conditions
Visual Acuity
Interventions
ACUVUE Oasys 1-Day, Precision 1
Device
Lead sponsor
Johnson & Johnson Vision Care, Inc.
Industry
Eligibility
18 Years to 40 Years
Enrollment
302 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
10
States / cities
Mission Viejo, California • Maitland, Florida • Orange Park, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2022 · Synced Oct 17, 2026, 10:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Compare the Pharmacokinetics of Two Different Tablets of Sotorasib in Healthy Participants

NCT05048784
View directory record Official record
Conditions
Healthy Participants
Interventions
Sotorasib
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 60 Years
Enrollment
145 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
Daytona Beach, Florida • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 18, 2023 · Synced Oct 17, 2026, 10:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Metformin and Furosemide Drug-Drug Interaction Study

NCT02028689
View directory record Official record
Conditions
Healthy
Interventions
Lesinurad 400 mg, Metformin 850 mg, Furosemide 40 mg
Drug
Lead sponsor
Ardea Biosciences, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 14, 2014 · Synced Oct 17, 2026, 10:59 AM EDT
Recruiting Phase 1 Interventional

Repeat PET/CT Imaging in People With CAPS and Anakinra-Induced Amyloidosis Using an Amyloid-Reactive Peptide to Measure Changes in Organ-Specific Amyloid Load

NCT06974877
View directory record Official record
Conditions
Cryopyrin-Associated Periodic Syndromes, Amyloidosis
Interventions
124I AT-01
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 120 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 17, 2026, 10:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Eyes-Closed Interoceptive Aerobic Exercise Compared With Matched Eyes-Open Treadmill Exercise in Healthy Adults

NCT07625371
View directory record Official record
Conditions
Exercise, Physical Activity, Healthy Adult, Interoception, Affect and Exertion During and Post-exercise
Interventions
Eyes-Closed Interoceptive Aerobic Exercise, Matched Eyes-Open Treadmill Exercise
Behavioral
Lead sponsor
Old Dominion University
Other
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 17, 2026, 10:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of Divarasib in Healthy Participants

NCT06835465
View directory record Official record
Conditions
Healthy Participants
Interventions
Divarasib, Rifampin
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Oct 17, 2026, 10:59 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Training Strategies to Maintain Performance

NCT07128511
View directory record Official record
Conditions
Shortness of Breath, Shortness of Breath/Dyspnea, Respiratory Distress
Interventions
Multiple Inhalation Breathing Pattern, Tactical Breathing Technique
Behavioral
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 45 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 19, 2025 · Synced Oct 17, 2026, 10:59 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Study of GS-4571 in Healthy Participants, Nondiabetic Obese Participants, and Nonobese Participants With Type 2 Diabetes Mellitus (T2DM)

NCT06562907
View directory record Official record
Conditions
Weight Management
Interventions
GS-4571, Placebo, Omeprazole
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
134 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
3
States / cities
Miami, Florida • San Antonio, Texas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 17, 2026, 10:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Visual Performance of Senofilcon A With and Without a New UV/HEV-filter

NCT05021081
View directory record Official record
Conditions
Visual Performance
Interventions
TRP-200, ACUVUE Oasys 1-Day
Device
Lead sponsor
Johnson & Johnson Vision Care, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Athens, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 26, 2023 · Synced Oct 17, 2026, 10:59 AM EDT
Recruiting Not applicable Interventional

Spectroscopic MRI Guided Proton Therapy in Assessing Metabolic Change in Pediatric Patients With Brain Tumors

NCT04908709
View directory record Official record
Conditions
Malignant Brain Glioma
Interventions
Magnetic Resonance Spectroscopic Imaging, Proton Therapy
Procedure · Device
Lead sponsor
Emory University
Other
Eligibility
Up to 21 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 17, 2026, 10:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

VNRX-5133 Drug-Drug Interaction in Healthy Adult Volunteers

NCT03332732
View directory record Official record
Conditions
Bacterial Infections
Interventions
VNRX-5133, VNRX-5022, Metronidazole, Placebo
Drug
Lead sponsor
Venatorx Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 18, 2018 · Synced Oct 17, 2026, 10:59 AM EDT